LIFR/CD118 (Leukemia Inhibitory Factor Receptor) Polyclonal

Leukemia Inhibitory Factor Receptor (LIFR) belongs to the type I cytokine receptor family. This protein combines with a high-affinity converter subunit, gp130, to form a receptor complex that mediates the action of the LIF that is involved in cellular differentiation, proliferation and survival in the adult and the embryo. LIF and LIFR are commonly over-expressed in many solid cancers and recent studies have implicated LIF/LIFR signaling plays a key role in tumor growth, progression, metastasis, stemness and therapy resistance. LIF/LIFR axis is implicated as a promising clinical target for cancer therapy. Defects in LIFR are the cause of Stueve-Wiedemann syndrome. LIFR expression identifies highly malignant melanocytic lesions at an early stage; and LIFR is associated with unfavorable prognosis in melanoma. LIFR also serves as a novel prognostic biomarker for gallbladder cancer.